Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study

BACKGROUND: The goal of induction therapy for multiple myeloma (MM) is to achieve adequate disease control. Current guidelines favor triplet (bortezomib-lenalidomide-dexamethasone; VRd) or quadruplet regimens (daratumumab, bortezomib-thalidomide-dexamethasone; D-VTd). In the absence of a direct comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Ja Min, Park, Sung-Soo, Yoon, Sung-Soo, Ahn, Ari, Kim, Myungshin, Lee, Jung Yeon, Jeon, Young-Woo, Shin, Seung-Hwan, Yahng, Seung-Ah, Koh, Youngil, Min, Chang-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310489/
https://www.ncbi.nlm.nih.gov/pubmed/37026379
http://dx.doi.org/10.5045/br.2023.2023005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310489/
https://www.ncbi.nlm.nih.gov/pubmed/37026379
http://dx.doi.org/10.5045/br.2023.2023005

Ejemplares similares